Stockrabit · Analysts
Questions across 4 calls

Piyush Nahar

Firm not listed in source transcripts

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited CC-Nov25.pdf · 2025-11-11
So Foram, I think what we have even guided at the star t of the year, we expect the margins to go up. So this quarter's 19.3% odd that we are seeing that includes the new Sanofi in -licensing that we did. So I think what we have guided for is we expect this year the base margins to improve by about 150 basis points. I think we'll be on track for that.
So Foram, when we have guided for FY '26, that was without any acquisitions. As you have noticed in this quarter end, basically in the last few months, we have acquired the remaining stake in Zuventus. So the debt increase that you are seeing is because of that. So I think with post that acquisition, we expect now to be debt-free by end of next year. So it'll take about 18 to 24 months.
Emcure Pharmaceuticals Limited CC-Mar25.pdf · 2025-05-22
So, I think for what we'll be looking at, the domestic, the target is to grow 200 basis points higher than the industry. So that will be about your low double digits type of growth. I think international is where we are expecting more around a mid-teens type of growth.
So, there is still some impact and as I think in the readout also, there is still about a 1% to 2% impact in the quarter. But I think that we'll be able to manage it out. So even in this quarter, if you look at it, ex FCM, we grew at 12%, including FCM, the growth was 10%. Namita, if you want to add on that.